HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase. Financial terms were not disclosed.
